Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat in ESRD Anemia (SIERRAS)
NCT02273726Phase 3Completed
- Sponsor
- FibroGen
- Start
- Jan 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of roxadustat in anemia of chronic kidney disease (2 arms), sponsored by FibroGen. Primary endpoint: Mean Hemoglobin Change From Baseline. Started Jan 2015; status: completed.
02
Drugs
roxadustat
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT02273726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273726.